SciELO - Scientific Electronic Library Online

 
vol.25 issue5Weight gain rate and feeding practices of low-socioeconomic status infantsMaturation process, body dissatisfaction and inappropriate eating behavior in young athletes author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Article

Indicators

Related links

  • Have no similar articlesSimilars in SciELO

Share


Revista de Nutrição

Print version ISSN 1415-5273

Rev. Nutr. vol.25 no.5 Campinas Sept./Oct. 2012

http://dx.doi.org/10.1590/S1415-52732012000500002 

ORIGINAL ORIGINAL

 

Effect of the classic ketogenic diet on the treatment of refractory epileptic seizures1

 

Efeito da dieta cetogênica clássica no tratamento de crises epilépticas refratárias

 

 

Luciana Duarte MartinsI;Vera Cristina TerraI; Carolina Ferreira NicolettiII; Paula Garcia ChiarelloII; Julio Sérgio MarchiniII; Américo Ceiki SakamotoI; Carla Barbosa Nonino-BorgesII


IUniversidade de São Paulo, Faculdade de Medicina de Ribeirão Preto, Hospital das Clínicas, Departamento de Neurologia, Psiquiatria, Psicologia e Médica. Ribeirão Preto, SP, Brasil
IIUniversidade de São Paulo, Faculdade de Medicina de Ribeirão Preto, Hospital das Clínicas, Departamento de Clínica Médica. Av. Bandeirantes, 3.900, 14048-900, Ribeirão Preto, SP, Brasil. Correspondence to/Correspondência para: CB NONINOBORGES. E-mail: carla@fmrp.com.br

 

 


ABSTRACT

OBJECTIVE:The ketogenic diet is used as a therapeutic alternative for the treatment of epilepsy in patients with refractory epilepsy. It simulates biochemical changes typical of fasting. The present study verified the nutritional impact of the ketogenic diet on children with refractory epilepsy.

METHODS: Nutritional status data (dietary, biochemical and anthropometric measurements), seizure frequency, and adverse events were collected from the medical records and during outpatient clinic visits of children over a period of 36 months.

RESULTS: Of the 29 children who initiated the ketogenic diet, 75.8% presented fewer seizures after one month of treatment. After six months, 48.3% of the patients had at least a 90.0% decrease in seizure frequency, and 50.0% of these patients presented total seizure remission. At 12 months, eight patients continued to show positive results, and seven of these children remained on the ketogenic diet for 24 months. There was an improvement of the nutritional status at 24 months, especially in terms of weight, which culminated with the recovery of proper weightforheight. There were no significant changes in biochemical indices (total cholesterol and components, triglycerides, albumin, total protein, creatinine, glycemia, serum aspartate transaminase and serum alanine transaminase). Serum cholesterol levels increased significantly in the first month, fell in the following six months, and remained within the normal limits thereafter.

CONCLUSION: In conclusion, patients on the classic ketogenic diet for at least 24 months gained weight. Moreover, approximately one third of the patients achieved significant reduction in seizure frequency, and some patients achieved total remission.

Indexing terms: Epilepsy. Ketogenic diet. Nutritional status.


RESUMO

OBJETIVO: A dieta cetogênica é empregada como uma terapia alternativa para o tratamento da epilepsia em pacientes com epilepsia refratária e simula as alterações bioquímicas de jejum. Neste trabalho, verificouse o impacto nutricional da dieta cetogênica em crianças com epilepsia refratária.

MÉTODOS: Os dados sobre o estado nutricional (bioquímica, alimentar e medidas antropométricas), a frequência de crises e os eventos adversos de crianças acompanhadas durante 36 meses foram coletados de prontuários médicos e visitas ambulatoriais.

RESULTADOS: Vinte e nove crianças iniciaram o tratamento; após um mês, 75,8% apresentaram redução das crises. Em seis meses, 48,3% dos pacientes tiveram pelo menos 90,0% de redução na frequência de crises, e, desses, 50,0% obtiveram o controle completo das crises. Aos doze meses, oito pacientes continuaram a apresentar Resultados positivos, e, desses, sete permaneceram em dieta cetogênica durante 24 meses. Observouse melhora do estado nutricional aos 24 meses de tratamento, especialmente em termos de peso, o que indica a recuperação da condição peso para altura. Não houve mudanças significativas nos índices bioquímicos analisados (colesterol total e de componentes, triglicerídeos, albumina, proteína total, creatinina, glicemia, transaminase glutâmico oxalacética sérica e transaminase glutâmico pirúvico sérica). Os níveis de colesterol aumentaram significativamente no primeiro mês, mas diminuíram nos seis meses seguintes e, posteriormente, se mantiveram dentro dos valores de referência.

CONCLUSÃO: Os pacientes em uso da dieta cetogênica clássica por pelo menos 24 meses apresentaram melhora de peso e cerca de um terço dos pacientes conseguiu uma redução significativa da frequência de crises, com alguns pacientes completamente livres delas.

Termos de indexação: Epilepsia. Dieta cetogênica. Estado nutricional.


 

 

INTRODUCTION

The Ketogenic Diet (KD), the socalled modified Atkins diet, and the lowglycemic index treatment have all emerged over the past decade as important therapeutic options for children with refractory epilepsy1,2. Whereas only a decade ago the KD was seen as a last resort, its global use now is more common1.

The KD simulates biochemical changes associated with fasting and is used especially in children with refractory epileptic seizures3. It could potentially be used in epileptic syndromes and specific conditions, providing specific benefits in conditions such as glucose transporter protein I (GLUT I) deficiency, pyruvate dehydrogenase deficiency (PDHD), myoclonicastatic epilepsy (Doose syndrome), tuberous sclerosis complex, Rett syndrome, and severe myoclonic epilepsy in infancy (Dravet syndrome)4,5. This diet can also be used by patients that do not tolerate the adverse side effects of anticonvulsant drugs3.

Fasting ketosis is mimicked by using fats to provide 90% of the dietary energy and the remainder 10% coming from carbohydrates and proteins6,7, to a limit of 75% of the recommended daily energy intake8. The term `ketogenic ratio' has been used to describe the ratio of ketoneproducing foods (for instance, dietary fat) to foods that reduce ketone production (for instance, carbohydrate and protein), and the most frequently used proportion is 4:1810. To provide the general principles of nutrition and meet the energy, protein, mineral and vitamin requirements, patients on the KD should take multivitamin and mineral supplements on a daily basis to improve and maintain their physiological wellbeing11.

The progress of refractory epilepsy in children submitted to multidrug treatment usually leads to neurological deterioration12. Moreover, frequent seizures and postseizure periods reduce the time a child remains awake, which may lead to low total energy intake. Side effects of antiepileptic drugs usually occur, and they increase with polytherapy. Among the undesirable effects are low appetite, difficulty chewing and swallowing, vomiting, malabsorption of nutrients like iron and zinc, and changes in energy balance. Therefore, repeated seizures and drug treatment may impair growth and cause nutritional problems, which are common in these children13-15.

Bertoli et al.16 reported that 40% of the children with refractory epilepsy have a low weightforage Zscore, and 24% have chronic undernourishment, that is, Low WeightforHeight (W/H) and HeightforAge (H/A) Zscores. In this same study, the mean daily energy intake was below the requirement, and inadequate macronutrient intake was evident. This suggested that the diet was high in proteins and lipids, and in low carbohydrates and fibers.

The ketogenic diet has been used for the treatment of refractory epilepsy for many years with good clinical results17. Its effectiveness has been reported in many studies, which have demonstrated significant reduction in seizure frequency18,19. The aim of this study was to evaluate the effect of a classic KD on nutritional status and seizure frequency in children with refractory epilepsy before, during, and after a sixmonth period of dietary treatment.

 

METHODS

The present study consisted of a retrospective and a prospective stage. The 29 participants had drugresistant epilepsy with more than one seizure daily and were thus placed on a KD. The KD was introduced during hospital stay, after a 24hour fast. After hospital discharge, the subjects were followed in outpatient clinics. This study was approved by the local Research Ethics Committee under protocol number 12267/2005, and an informed consent was signed by all the participants' legal guardians.

The study demographic data included sex, age at epilepsy onset, age at KD introduction, epileptic syndrome diagnosis according to the classification of the International League Against Epilepsy (ILAE)20, Magnetic Resonance Imaging (MRI) and electroencephalogram (EEG) findings, seizure frequency before and after KD introduction, and clinical complications. The antiepileptic drug was not changed for at least six months after KD initiation, and then it was progressively reduced in seizurefree patients.

The use of vitamin and mineral supplements (Table 1) was initiated after KD introduction; evaluation of their necessity and efficacy was done by laboratory tests. The KD was immediately halted when there was no improvement within 2 months. KD interruption was abrupt, without a progressive reduction in the amount and ratio of fat intake.

 

 

Anthropometric assessment included weight, height, W/H and H/A according to the criteria established by Waterlow21. This method allowed the calculation of W/H and H/A adequacy with respect to the 50% weight and height percentiles of the National Center for Health Statistics (NCHS) standards22. Laboratory tests were also done to investigate possible nutritional deficiencies and diseases associated with the KD. The levels of albumin, total proteins, triglycerides, total cholesterol, Low Density Lipoproteincholesterol (LDL-c), High Density Lipoproteincholesterol (HDL-c), vitamin A, beta carotene, iron, calcium, phosphorus, potassium, sodium, zinc, magnesium, glycemia, urea, creatinine, Aspartate Transaminase (AST) and Alanine Transaminase (ALT) were measured and complete blood count done. Patients were examined at 1, 6, 12 and 24 months after KD introduction and 12 months after KD discontinuation.

The efficacy of the KD was assessed by means of seizure activity on the basis of seizure frequency recorded by the participants' parents.

 

RESULTS

Demographic data

Thirteen (44.8%) of the 29 patients were boys. The mean age at epilepsy onset was 6.5 months (ranging from 0 to 30 months), and the mean age at the beginning of the KD diet was 6.1, Standard Deviation (SD)=3.4 years (ranging from 1 to 15 years). Subjects were kept on the KD for a mean of 11 (SD=11) months. Seizure types included generalized symptomatic (62%), focal symptomatic (24.1%), generalized cryptogenic (10.3%), and focal cryptogenic (3.6%) events. Fifty percent of the patients with generalized symptomatic epilepsy had LennoxGastaut syndrome (9/18 patients). MRI findings were: cortical developmental abnormalities (34.5%), diffuse cortical atrophy (34.5%), gliosis (13.7%) and congenital infection (3.6%). MRI was normal for four patients. All patients had developmental delays, and delay was severe in 75.9% and moderate in 24.1% of the children. Seizure frequency ranged from three to numerous seizures daily.

All patients were submitted to interictal electroencephalogram before the introduction of the KD, revealing abnormal baseline activity. Almost all of them had moderate disorganization (27/29). Multifocal interictal epileptiform discharges were observed in high, moderate, and rare incidences in 17, 10, and 2 patients, respectively. All patients with LennoxGastaut syndrome had a high incidence of spikes.

Nutritional assessment and side effects

During hospital stay and before KD initiation, 34.5% of the participants had normal weight and 65.5% were undernourished; 51.7% had acute and 10.3% had chronic undernutrition, and 3.5% had had undernutrition in the past.

Of the seven participants that stayed on the KD until the end of the study, 14.3% had normal weight before starting the diet. The remainder 85.7% were undernourished, all of which had acute undernutrition. At the end of the study, patients presented with improved nutritional status, especially in terms of weight, recovering proper W/H. The final results were as follows: 28.6% of the subjects had normal weight, 71.4% were undernourished, 42.8% had had undernutrition in the past, that is, were presently stunted, and only 28.6% presented chronic undernutrition (Figure 1).

 

 

Analysis of biochemical parameters evidenced a significant rise in serum cholesterol levels in the first month, followed by a reduction at six months, and maintenance of constant values thereafter, with no significant differences six months after KD was discontinued (Figure 2).

 

 

There was no significant difference in the mean triglyceride levels during the KD, but 6.9% (2/29) of the participants had hypertriglyceridemia but the levels went back to normal at the end of the diet. Blood glucose of only one patient (1/29) did not stay within the reference values.

There were no changes in serum albumin in the first 6 months of the study. Only one patient (1/29) experienced severe hypoalbuminemia at 11 months, so the treatment was discontinued. There were no significant differences in serum albumin concentrations or in total serum protein concentrations of the other subjects throughout the study period,.

Six individuals (20.7%) had high AST and ALT levels before the beginning of the KD. The liver function of these patients became normal after some time on the diet, and serum AST and ALT levels were within the normal ranges (Figure 3).

 

 

The mean vitamin A, iron, calcium, phosphorus, potassium, sodium, zinc, magnesium, blood glucose, urea, and creatinine levels did not vary significantly throughout the study.

In the beginning of the KD, two patients discontinued treatment: one due to complications in the ventriculoperitoneal shunt (VP shunt) and another because of persistent vomiting. The commonest side effects after the initial stage of the diet were gastrointestinal symptoms (9/29): 6 patients had nausea and vomiting, 2 presented with constipation or diarrhea, and 1 experienced difficulty taking in fluids and accepting the diet. Two children had dehydration and severe metabolic acidosis, which led to hospitalization. They were intravenously hydrated with glucosefree solutions or lactate. In the longterm, the patients presented with other complications such as hypoalbuminemia, hypoproteinemia, waterelectrolyte imbalance, kidney stones, hypercholesterolemia, low fluid intake and refusal of the diet.

Seizure frequency over time

Only 7 of the initial 29 patients remained on the KD until the end of the study (Table 2). Within the first months of the diet, seven subjects dropped out of the study because of unresponsiveness to treatment; the seizure frequency of the remainder participants dropped so they stayed on the diet, and three children became seizurefree. At six months, five more children were excluded from the study for unresponsiveness; three were excluded because of adverse events; and 14 children had at least a 90% reduction in seizure frequency. Of the eight participants that were still on the diet at 12 months, four were completely seizurefree and four had a 90% reduction in seizure frequency. At 24 months, one patient presented with kidney stones and discontinued the treatment. At the end of 24 months, all patients discontinued the KD and were followed for another 12 months. During this period, five patients remained seizurefree and two patients had an increase in seizure frequency.

The dosages of the antiepileptic drug of patients with reduced seizure frequency and seizurefree were reduced. At the end of the study, two patients were medicationfree and remained with the same seizure frequency or absence as the previous year, when KD was discontinued. Two participants continued taking the same dosage, and the dosages of three were reduced.

 

DISCUSSION

The retrospective assessment of 29 patients and the followup of seven children with refractory epilepsy placed on the classic KD resulted in good seizure control. Recovery of the nutritional status is essential for the proper growth and development of the patients, and the effect of the KD in this process is not clear. There are few studies on the risks posed by the KD, mainly with respect to its nutritional impact23. Studies have reported significant weight and height gains after 4 to 6 months of a KD24. Another similar study assessed the growth of children placed on a KD for one year and found that height and weight remained within the normal range; at the end of the study period, growth was similar to that of normal children. In contrast, Williams et al.25 reported that children on a KD followed for 1.2 years presented suboptimal growth, emphasizing the need for the nutritional followup of patients treated with this diet. Similar results have been observed by other authors. Tumas et al.26 demonstrated a decrease in mean weightforage and H/A in 20 patients using a KD followed for 12 months, whereas Peterson et al.27 detected significant reduction of H/A and W/A Z-scores and percentiles in children using a KD for 12 months.

In the present study, there was a high percentage of previously undernourished patients, but after the 24-month study period or longer, these patients reached a normal weight. This result confirms the findings of Liu et al.24 and is probably related to adequate daily energy intake. However, considering the longterm effect of the KD on growth rates, the height of the present sample did not recover after a 24-month followup. Liu et al.24 observed height recovery after a short followup period, but other studies involving the use of KD and longer followups did not corroborate their findings, suggesting that patients on longterm use of KD should be closely monitored26,27.

Some studies have evidenced a slight rise in total cholesterol and triglyceride levels in children on the KD because of refractory epilepsy28. Hosain et al.29 demonstrated that total cholesterol and triglycerides significantly increased in 14.5% and 36.2% of the patients on a KD, respectively; however, cholesterol concentrations higher than 230mg/dL and serum triglyceride levels higher than 190mg/dL were considered high in their work. Liu et al.24 have compared the classic KD with the KD based on mediumchain triglycerides (MCT) and showed that patients following the classic KD had increased total cholesterol and LDL levels, whereas those that received MCT had significant reduction in total cholesterol and LDL, with increased HDL.

Laboratory tests revealed similar results for serum albumin, blood glucose and liver enzymes when compared with baseline findings during KD use. These data agree with those published by other authors14,30.

The efficacy of the KD for the treatment of epilepsy is currently widely accepted. Kang et al.31 have described that after a 12month period on the classic KD, 23 to 44% of the patients had a 50% decrease in seizure activity, and 7% to 22% of these were completely seizure-free.

In a study with patients following a KD, Hartman & Vining32 investigated how age, sex, epileptic syndrome, and electrographic pattern affected KD efficacy, but these authors did not find anything significant. Hence, these authors suggested that KD should be considered an alternative treatment for any patient with drugresistant epilepsy.

 

CONCLUSION

Despite the small size of our sample, our results corroborate the use of KD as an important and effective alternative for the treatment of patients with refractory epilepsy. However, a more detailed nutritional followup is essential to ensure appropriate nutrition to the growth and development of these patients.

 

CONTRIBUTOR

LD Martins was responsible for the experimental design, data collection and analysis, and writing of the manuscript. CF Nicoletti was responsible for data collection and writing of the manuscript. CB Nonino was responsible for the experimental design, data analysis, provision of significant advice, consultation, and supervision of the study. JS Marchini, VC Terra, AC Sakamoto, and PG Chiarello were responsible for data analysis, provision of significant advice, and consultation. All authors were responsible for the critical revision of the manuscript for important intellectual content.

 

REFERENCES

1.Kossoff EH, ZupecKania BA, Rho JM. Ketogenic diets: an update for child neurologists. J Child Neurol. 2009; 24(8):97988.         [ Links ]

2.Kessler SK, Neal EG, Camfield CS, Kossoff EH. Dietary therapies for epilepsy: future research. Epilep Behav. 2011; 22(1):1722.         [ Links ]

3.Kossoff EH, ZupecKania BA, Amark PE, et al. Optimal clinical management of children receiving the ketogenic diet: recommendations of the International Ketogenic Diet Study Group. Epilepsia. 2009; 50(2):30417.         [ Links ]

4.Bainbridge JL, Gidal BE, Ryan M. The ketogenic diet. Pharmacoterapy. 1999; 19(6):7826.         [ Links ]

5.Kelley SA, Kossoff EH. Doose syndrome (myoclonicastatic epilepsy): 40 years of progress. Dev Med Child Neurol. 2010; 52:98893.         [ Links ]

6.Schwartz RH, Eaton J, Bower BD. Ketogenic diets in the treatment of epilepsy: shortterm clinical effects. Dev Med Child Neurol. 1989; 31(2):14551.         [ Links ]

7.The American Dietetic Association. Manual of clinical dietetics. Chicago: The American Dietetic Association; 1998. p.45566.         [ Links ]

8.Freeman JM, Vining EPG, Pillas DJ, Pyzik PL, Casey JC, Kelly LM. The efficacy of ketogenic diet: a prospective evolution of intervention in 150 children. Pediatrics. 1998; 102(6):135863.         [ Links ]

9.Neal EG, Cross JH. Efficacy of dietary treatments for epilepsy. J Hum Nutr Diet. 2010; 23:1139.         [ Links ]

10.Huffman J, Kossoff HE. State of the ketogenic diet(s) in epilepsy. Epilepsia. 2007; 48:4358.         [ Links ]

11.Katyal NG, Koehler AN, McGhee B, Foley CM, Crumrine PK. Ketogenic diet in refractory epilepsy: the experience of children's Hospital of Pittsburgh. Clin Pediatr. 2000; 39(3):1539.         [ Links ]

12.Artigas J. Psychological manifestations of epilepsy in childhood. Rev Neurol. 1999; 28(Suppl 2): S13541.         [ Links ]

13.Volpe SL, Schall JI, Gallagher PR, Stallings VA, Bergqvist AGC. Nutrient intake of children with intractable epilepsy compared with healthy children. J Am Diet Assoc. 2007; 107(6):101418.         [ Links ]

14.Richard D, Ferland J, Lalonde J, Samson P, Deshaies Y. Influence of topiramate in the regulation of energy balance. Nutrition. 2000; 16(10):9616.         [ Links ]

15.Thommessen M, Kase BF, Riis G, Heiberg A. The impact of feeding problems on growth and energy intake in children with cerebral palsy. Eur J Clin Nutr. 1991; 45(10):47987.         [ Links ]

16.Bertoli S, Cardinali P, Veggiotti P, Trentani C, Testolin G, Tagliabue A. Evaluation of nutritional status in children with refractory epilepsy. Nutr J. 2006; 5: 1422.         [ Links ]

17.Mainardi P, Albano C. Is the antiepileptic effect of the ketogenic diet due to ketones? Med Hypotheses. 2008; 70(3):5369.         [ Links ]

18.Wheless JW. Nonpharmacologic treatment of the catastrophic epilepsies of childhood. Epilepsia. 2004; 45(Suppl 5):S1722.         [ Links ]

19.Hauser W, Hesdorffer DC. The natural history of seizures. In: Wyllie E. The treatment of epilepsy: principles and practice. Baltimore: Williams & Wilkins; 1996. p.1738.

20.Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia. 1989; 30(4):38999.         [ Links ]

21.Waterlow JC. Note on the assessment and classification of proteinenergy malnutrition in children. Lancet. 1973; 14(2):879.         [ Links ]

22.National Center for Health Statistics. NCHS Growth curves for children birth 18 years. Washington (DC): Government Printing Office; 1977. Departament of Health Education and Welfare publication nº (PHS) 781650. Vital and Health Statistics; serie 11; n.165.

23.Papandreou D, Pavlou E, Kalimeri E, Mavromichlis I. The ketogenic diet in children with epilepsy. Br J Nutr. 2006; 95(1):513.         [ Links ]

24.Liu YMC, Williams S, BasualdoHommond C, Stephens D, Curtis R. A prospective study: growth and nutrition status of children treated with the ketogenic diet. J Am Diet Assoc. 2003; 103(6): 70712.         [ Links ]

25.Williams S, BasualdoHammond C, Curtis R. Growth retardation in children with epilepsy on the ketogenic diet: a retrospective chart review. J Am Diet Assoc. 2002; 102(3): 4057.         [ Links ]

26.Tumas R, Lopes Cardoso A, Marquesdias MJ, Vieira MA. Ketogenic diet in epileptic children: clinical and laboratory assessment. Nutr Hosp. 2010; 25(2): 3178.         [ Links ]

27.Peterson SJ, Tangney CC, PimentelZablah EM, Hjelmgren B, Booth G, BerryKravis E. Changes in growth and seizure reduction in children on the ketogenic diet as a treatment for intractable epilepsy. J Am Diet Assoc. 2005; 105(5):71825.         [ Links ]

28.Freeman JM, Kossof EH, Hartman AL. The ketogenic diet: one decade later. Pediatrics. 2007; 119: 53543.         [ Links ]

29.Hosain SA, Vegatalbott ML, Solomon GE. Ketogenic diet in pediatric epilepsy patients with gastrostomy feeding. Pediatr Neurol. 2004; 32(2): 813.         [ Links ]

30.Kim DW, Kang HC, Park JC, Kim HD. Benefits of the nonfasting ketogenic diet compared with the initial fasting ketogenic diet. Pediatrics. 2004; 114(6):162730.         [ Links ]

31.Kang HC, Kim YJ, Kim DW, KimHD. Efficacy and Safety of the ketogenic diet for intratable epilepsy: korean multicentric experience. Epilepsia. 2005; 46(2):2729.         [ Links ]

32.Hartman AL, Vining EPG. Clinical aspects of the ketogenic diet. Epilepsia. 2007; 48(1):3142.         [ Links ]

 

1Artigo elaborado a partir da dissertação de LD MARTINS, intitulada "Efeito da dieta cetogênica clássica no tratamento de crises epilépticas refratárias". Universidade de São Paulo; 2007.

 

 

Received on: 27/5/2011.
Final version on: 4/6/2012.
Approved on: 25/6/2012.